KPTI Latest Press Releases

-- October 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- September 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:06 PM

-- August 31, 2026 --

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PRNewswire 7:30 AM

-- August 27, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 6:28 PM

-- August 25, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI Globe Newswire 6:26 PM

-- August 20, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 10:01 AM

-- August 13, 2026 --

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PRNewswire 7:30 AM

-- August 11, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI Globe Newswire 6:21 PM

-- August 10, 2026 --

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PRNewswire 7:30 AM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 11:02 PM

-- August 4, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI Globe Newswire 4:51 PM

-- August 3, 2026 --

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- July 30, 2026 --

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PRNewswire 4:06 PM

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PRNewswire 4:05 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 10:01 AM

-- July 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- June 3, 2026 --

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PRNewswire 4:15 PM

-- June 2, 2026 --

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PRNewswire 10:03 AM

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology PRNewswire 9:00 AM

-- June 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation PRNewswire 7:30 AM

Market Data Delayed 15 Minutes